| Literature DB >> 19329776 |
Jianhua Yu1, Maxim Ershler, Li Yu, Min Wei, Björn Hackanson, Akihiko Yokohama, Takeki Mitsui, Chunhui Liu, Hsiaoyin Mao, Shujun Liu, Zhongfa Liu, Rossana Trotta, Chang-gong Liu, Xiuping Liu, Kun Huang, Jan Visser, Guido Marcucci, Christoph Plass, Alexander V Belyavsky, Michael A Caligiuri.
Abstract
Aberrant methylation of tumor suppressor genes can lead to their silencing in many cancers. TSC-22 is a gene silenced in several solid tumors, but its function and the mechanism(s) responsible for its silencing are largely unknown. Here we demonstrate that the TSC-22 promoter is methylated in primary mouse T or natural killer (NK) large granular lymphocyte (LGL) leukemia and this is associated with down-regulation or silencing of TSC-22 expression. The TSC-22 deregulation was reversed in vivo by a 5-aza-2'-deoxycytidine therapy of T or NK LGL leukemia, which significantly increased survival of the mice bearing this disease. Ectopic expression of TSC-22 in mouse leukemia or lymphoma cell lines resulted in delayed in vivo tumor formation. Targeted disruption of TSC-22 in wild-type mice enhanced proliferation and in vivo repopulation efficiency of hematopoietic precursor cells (HPCs). Collectively, our data suggest that TSC-22 normally contributes to the regulation of HPC function and is a putative tumor suppressor gene that is hypermethylated and silenced in T or NK LGL leukemia.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19329776 PMCID: PMC2689053 DOI: 10.1182/blood-2009-02-205732
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113